ARTICLE | Company News
Cephalon submits OraVescent NDA
September 7, 2005 1:24 AM UTC
CEPH submitted an NDA to FDA for OraVescent fentanyl buccal tablet to manage breakthrough cancer pain. The submission was based on data from 13 trials and included a risk minimization action plan for ...